Multivalent FZD4, Wnt Co-receptor, and VEGF Binding Molecules

EyeBiotech Limited published US Patent Application US20260092125A1 for multivalent antibody binding molecules comprising FZD4 receptor binding, LRP5 co-receptor binding, and VEGF binding domains that activate the Wnt/β-catenin signaling pathway. The application covers the molecules, nucleic acids, vectors encoding them, and methods of use. Inventors include Paul E. Stephens, Michael John Davies, Yin Shan Eric Ng, Masahisa Handa, and Alexander V. Loktev. The application was filed September 4, 2025, and published April 2, 2026.

Anti-NRP2 Antibody Compositions and Methods for Treating NRP2-Associated Diseases

The USPTO published patent application US20260092122A1 for affinity-matured and humanized antibodies targeting human neuropilin-2 (NRP2) polypeptides. The application (No. 19293892, filed August 7, 2025) names six inventors and covers therapeutic compositions and methods for modulating NRP2 activity to treat NRP2-associated diseases, including cancer (A61P 35/04).

Treatment of Cancer Using Anti-HLA-G/Anti-CD3 Bispecific Antibody and 4-1BB Agonist

The USPTO published patent application US20260092118A1 by Hoffmann-La Roche Inc., covering a method for treating cancer using an anti-HLA-G/anti-CD3 bispecific antibody in combination with a 4-1BB (CD137) agonist. The application (No. 19325175) was filed September 10, 2025, and lists Meher Majety, Carina Hage, and Johannes Sam as inventors. This publication represents an early-stage intellectual property filing for a bispecific antibody-based cancer therapy.

Bladder Cancer Classification and Treatment Using Atezolizumab

The USPTO published patent application US20260092117A1 disclosing methods for classifying and treating bladder cancer (including locally advanced or metastatic urothelial cancer) using atezolizumab, a PD-1 axis binding antagonist. The application covers diagnostic methods, treatment regimens, compositions, kits, and articles of manufacture for bladder cancer classification and therapy. The application was filed on April 4, 2025.

B7H3/PDL1 Bispecific Antibody Cancer Therapeutic

The USPTO published patent application US20260092116A1 by DARTSBIO Pharmaceuticals Ltd. covering a B7H3/PDL1 bispecific antibody for cancer treatment. The invention comprises a monoclonal antibody targeting PDL1 linked to nano-antibodies targeting B7H3, designed to relieve T-cell inhibition while targeting tumor cells. The application was filed October 13, 2022, with six inventors.

Anti-CTLA-4 antibodies with variant Fc regions

The USPTO published patent application US20260092115A1 for anti-CTLA-4 antibodies featuring variant Fc regions and methods of production and use. The application (No. 19407391) was filed December 3, 2025, by a team of 11 inventors including researchers from pharmaceutical companies. The invention relates to therapeutic antibodies modified to enhance effector functions through Fc region engineering.

Treatment of Lung Cancer Using Anti-PD-1 Antibody Combination

The USPTO published Bristol-Myers Squibb Company's patent application (US20260092114A1) for a method of treating lung cancer using a combination of an anti-PD-1 antibody administered by infusion in under 60 minutes and optionally an anti-CTLA-4 antibody administered in under 90 minutes. The application was filed on September 29, 2025.

CD28/OX40 Bispecific Antibodies for Solid Organ Transplant Rejection Treatment

The USPTO published patent application US20260092113A1, filed by Bristol-Myers Squibb, covering methods for treating solid organ transplant rejection using CD28/OX40 bispecific antibodies. The application (No. 19237572) claims a multispecific binding protein with a VHH domain targeting CD28 and a VH/VL domain targeting OX40. Inventors include Rami Lissilaa, Benjamin Suratt, and Jessica Voss.

Anti-CTLA-4 Antibodies for Treating Adenoid Cystic Carcinoma

The USPTO published patent application US20260092112A1 covering uses of anti-CTLA-4 antibodies for treating adenoid cystic carcinoma. Inventors Yang Liu and Pan Zheng filed Application No. 19112015 on September 15, 2023, with the application published April 2, 2026. The invention claims therapeutic applications of anti-CTLA-4 antibodies specifically for adenoid cystic carcinoma.

TREM2 antibodies patent, neurodegenerative disease treatment, 2nd Apr

TREM2 antibodies patent, neurodegenerative disease treatment, 2nd Apr